This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Sources searched to identify primary studies
The probabilities of PCI and CABG were obtained from the invasive arm of a contemporary trial of invasive and conservative treatment of ACS. Relative risks and odds ratios from randomised controlled trials of GP IIb/IIIa inhibitors in ACS patients were used to derive other probabilities. Major bleeding rates were derived from pooled estimates of bleeding rates in randomised controlled trials of ACS. The life expectancy of patients was derived from vital statistics data or from Kaplan-Meier estimates from published studies.
Methods used to judge relevance and validity, and for extracting data
A review of the literature was conducted to derive the effectiveness and epidemiological data needed to populate the model. However, the methods of the review were not reported. The effectiveness and epidemiological data were derived from published studies. When necessary, the authors pooled estimates from different studies in order to derive a single measure of effectiveness.
Measure of benefits used in the economic analysis
The authors stated that the main measure of benefit was the life-years (LYs). However, they also calculated the qualityadjusted life-years (QALYs) gained. The authors did not report the methods used to convert LYs into QALYs gained, although they referenced the source used to derive the utilities. Discounting was relevant, as lifetime outcomes were estimated, and was appropriately performed at an annual rate of 3%.
Direct costs
The direct costs to the health care service were included in the analysis. These comprised the costs of abciximab and small molecule GP IIb/IIIa inhibitor, and the costs of procedures and hospital stay. The 30-day and 6-month costs of procedures and hospital stay were derived from a published trial, whereas the costs incurred after 6 months were derived from projections for a typical 60-year-old MI patient from the Cholesterol And Recurrent Events trial population (Tsevat et al. 2001 , see 'Other Publications of Related Interest' below for bibliographic details). The authors assumed the number of abciximab vials used per patient and derived the unit cost for each vial from published sources. The costs of GP IIb/IIIa inhibitor were derived from results from a published trial. Since the costs could be incurred over the lifetime of the patient, discounting was relevant and was appropriately performed at an annual rate of 3%. The price year was 2002. The study reported the average costs. The costs and the quantities were not reported separately.
